<DOC>
	<DOC>NCT00198432</DOC>
	<brief_summary>To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.</brief_summary>
	<brief_title>Chemoradiotherapy of NSCLC Stage IIIB</brief_title>
	<detailed_description>Chemotherapy: C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m² Radiotherapy: 66 Gy with 33 fractions (2 Gy/fraction, 1 fraction/day, 6,5 weeks) High energy Photons X (&gt;= 9MV)</detailed_description>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>NSCLC stage IIIA N2 or IIIB not resectable, except N3 susclavicular, nor reached pleural PS = 0 or 1 Possibility of including all the targets in only one exposure field Slimming &lt; 10% of the weight of the body Functions hepatic, renal and hematologic normal VEMS &gt;40% and PaO2 &gt;60 mmHg written and signed informed consent Exclusion criteria : NSCLC stage IV or wetIIIB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>